Health ❯Medicine ❯Pharmacology

Weight Loss

Medical Treatments Dietary Interventions Hormones Pharmaceuticals Clinical Studies Chronic Diseases Anti-Obesity Drugs Cardiovascular Health Medication Risks Obesity

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research

UK Nears One Million Users of Weight-Loss Jabs as New Benefits and Risks Emerge

Rising Use of Ozempic Raises Health, Ethical, and Social Concerns